Al-Modawat Specialized Medical Valuation
Is 9594 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9594 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9594 (SAR14.9) is trading above our estimate of fair value (SAR7.03)
Significantly Below Fair Value: 9594 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9594?
Key metric: As 9594 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 9594's PE Ratio? | |
|---|---|
| PE Ratio | 32.6x |
| Earnings | ر.س10.85m |
| Market Cap | ر.س353.88m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.6x |
| Enterprise Value/EBITDA | 21.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 9594's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.5x | ||
9546 Naba Al Saha Medical Services | 22.6x | n/a | ر.س851.6m |
4009 Middle East Healthcare | 29.6x | 21.4% | ر.س6.3b |
4007 Al Hammadi Holding | 19.4x | 9.4% | ر.س6.3b |
4005 National Medical Care | 26.5x | 11.5% | ر.س7.3b |
9594 Al-Modawat Specialized Medical | 32.6x | n/a | ر.س353.9m |
Price-To-Earnings vs Peers: 9594 is expensive based on its Price-To-Earnings Ratio (32.6x) compared to the peer average (24.5x).
Price to Earnings Ratio vs Industry
How does 9594's PE Ratio compare vs other companies in the Asian Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 9594 is expensive based on its Price-To-Earnings Ratio (32.6x) compared to the Asian Healthcare industry average (21x).
Price to Earnings Ratio vs Fair Ratio
What is 9594's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 32.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 9594's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.